Breast Cancer Metastasis to Spine: Survival Rate

Breast cancer that has spread to the spine is treatable but usually not curable, and many people live with it for years rather than months. Among cancers that spread to the spine, breast cancer has one of the longest survival times.¹ The range between individuals is wide, though, and the biggest single clue sits in the tumor’s own biology, not in the spine.

How Long People Typically Live After Spread to the Spine

Survival is usually reported as the time by which half of people were still alive, so half lived longer. Across one group of breast cancer patients, half were still alive about 44 months, nearly 3.7 years, after the spine spread was found.² In a cancer center group who needed spine surgery, half were alive at about 17 months.³ People who need surgery often have pressure on the nerves or an unstable spine, so they tend to be sicker to begin with. Even so, after spine surgery, about half of breast cancer patients were alive at 5 years, roughly double the rate for lung or kidney cancer.⁴

A median says nothing about where one person will land, and it is not a countdown. Survival curves have a long tail, so some people live many years beyond it. Each number also describes only the people in that study, who may have been sicker or healthier than you. Your oncologist can place you within the range using your subtype, treatments and overall health.

The numbers you find online disagree for good reasons. Some studies start the clock when the spine spread was found, others at the date of surgery, and a later start usually gives a shorter figure. Some groups include mostly fast-growing subtypes, which pulls their typical survival down. Groups treated in different years received different drugs. And studies of surgical patients include only people sick enough to need an operation, while others include everyone with spine spread.

Outlook has also improved. Among older U.S. patients having spinal fusion surgery, half lived 12.4 months in 1986–1995 and 19.6 months in 1996–2005.⁵ At one cancer center, people operated on after 2016 had a 69% lower risk of death than earlier patients.⁶

Breast Cancer Subtype Changes the Outlook Most

Your pathology report labels the tumor by whether it has hormone receptors (ER/PR) and the HER2 protein. Hormone receptor-positive cancers feed on estrogen or progesterone. HER2-positive cancers make extra HER2. Triple-negative cancers have none of the three.

The pattern holds in surgical patients. After spine surgery, people with hormone-positive plus HER2-positive tumors lived a median of 48 months, and triple-negative only 5 months.¹⁰ Slow-growing hormone-positive tumors had a median of 39 months, versus 20 months for faster-growing ones.¹¹ One year after surgery, 63% of hormone-positive patients were alive versus 12% of triple-negative patients.¹² Part of the reason is that hormone-positive and HER2-positive cancers have targeted drugs that triple-negative cancer largely lacks.

To find your own subtype, look for lines labeled ER, PR and HER2 on your report. Each is usually reported as positive or negative, sometimes with a percentage or a score. The tumor in the spine can differ from the original breast tumor, so doctors sometimes biopsy a spine lesion to check, and the result can change the treatment plan.

A triple-negative diagnosis carries the lowest figures, but they come from fairly small groups, many treated before newer options existed, so they may understate what is possible now. Immunotherapy and newer antibody-based drugs are now used for some triple-negative cancers, though they do not help everyone. Because standard options are fewer, it is worth asking whether a clinical trial fits your situation.

Other Factors That Shape Survival

Walking ability is a strong signal. When cancer pressed on the spinal cord, 66% of people who could walk after radiation were alive at one year, versus 10% who could not.¹³ Nerve problems before surgery also predicted shorter survival.¹⁴ That is why fast treatment of new weakness protects both function and outlook.

The extent of spread matters too. Women with a single bone metastasis lived longer than those with several.¹⁵ Other bone metastases alongside the spine predicted shorter survival after surgery.¹⁶ Spread to organs such as the liver or lungs cut one-year survival from 82% to 18% in one group.¹⁷ Two other surgical studies found organ spread did not change survival.¹⁸¹⁹

The disagreement has simple explanations. Many of these studies are small, so a handful of patients can swing the result either way. Surgical studies include only people judged fit for an operation, so those with organ spread may have been healthier than most. Treatment for organ spread has also improved over the years. What matters for you is how your own organ involvement is responding to treatment, which is worth asking your oncologist about.

Age and body strength play a part. Women over 50 had somewhat shorter survival in one group with unstable spine metastases.²⁰ People with the smallest back muscles on scans lived a median of about 7 months, versus 19 months with the largest.²¹

Some factors matter less than people fear. In one group, an unstable spine did not by itself shorten survival,²² which suggests that stabilizing it is about function and comfort rather than lifespan alone. Studies disagree about whether the part of the spine involved changes survival, so location is not a firm predictor.

What Treatment Does for Survival and Daily Life

Drugs drive long survival because they work throughout the body. For hormone-positive, HER2-negative cancer, a hormone pill plus a CDK4/6 inhibitor is a standard first treatment. With this combination, about 77% of people were alive at 2 years and half lived 55 to 65 months.²³ All three CDK4/6 drugs worked about equally.²⁴ These figures cover spread anywhere, not only the spine. Denosumab or IV bisphosphonates such as zoledronic acid reduce fractures and other bone complications. Denosumab delayed first bone complications slightly more than IV bisphosphonates and cut the need for bone radiation.²⁵

Surgery removes tumor pressing on the cord and stabilizes the spine. In one group, all patients’ symptoms improved and none had regrowth at 6 months.²⁶ In another, no patient got worse and several walked better within 30 days.²⁷ Daily functioning scores rose after surgery.²⁸ Some people had complications, such as bleeding that required a second operation.²⁹

Focused high-dose radiation and standard radiation give similar control and survival overall.³⁰ After focused radiation for painful spine metastases, 60% were alive at 1 year and 21% at 5 years.³¹ For a collapsed vertebra, cement injection controlled pain in all reported cases in one small group.³²

Some symptoms need care right away. New leg weakness, numbness or difficulty walking calls for same-day contact with your cancer team or an emergency department, because the spinal cord may be under pressure. Losing control of the bladder or bowels, or being unable to urinate, is an emergency. Severe new back pain that is worse at night or when lying flat should be reported promptly, even without weakness.

Good questions for your team: Is my spine stable? Am I a candidate for surgery or focused radiation? Should I take a bone-strengthening drug, and what about dental checks? Which drug fits my subtype?

How Doctors Estimate Your Own Outlook

Doctors combine factors such as subtype, walking, organ spread and blood tests into scores that guide treatment. The SORG tool was most accurate for predicting 30- and 90-day survival after spine surgery.³³ The revised Katagiri score performed consistently in breast cancer.³⁴ In untreated patients, SORG was best at predicting survival at 6 months and 1 year.³⁵ Even the best tools are often wrong for individuals. They were built on patients treated in earlier years, may not reflect new drugs, and people with breast cancer often outlive predictions.

A score helps a surgeon judge whether an operation is likely to give enough good time to be worth its risks and recovery. A low predicted survival may steer the team toward lighter treatment, such as radiation alone. It is one input alongside your symptoms, scans and wishes, not a verdict, and it is reasonable to ask what your score is and whether it changed the plan.

If the Cancer Comes Back in the Spine

The same spot can often be safely treated again with careful planning.³⁶ About 65% had pain relief after re-irradiation.³⁷ After focused re-irradiation, 61% were alive at 1 year, with 12% regrowth and 9% fracture.³⁸ In another report, about 20% had regrowth, often more than a year later.³⁹

New or returning pain in a treated area is the most common early sign that the cancer may be growing again, and it should be reported rather than waited out. New weakness or numbness in the legs or arms should also be reported quickly, since it can mean pressure on the spinal cord. Ask how often follow-up MRI scans are planned, so you are not relying on symptoms alone.

Managing the Costs of Care

About 25% of people with brain or spine metastases reported serious financial strain from their care.⁴⁰ Emergency visits and job changes raised the risk, so a sudden problem can be the trigger.⁴¹ Patient money strain often matches family strain,⁴² since a spouse or relative may cut work hours to provide care.

Your cancer center can connect you with a financial counselor, who can explain your coverage and what bills to expect. Drug manufacturers or charities may offer assistance programs for expensive medicines. Calling early about new symptoms lets problems be handled in the clinic rather than the emergency room. If costs are making you delay or skip care, tell your team, since they may be able to adjust the plan or point you to help.